Tuberculosis (TB) is one of the most important infectious diseases affecting a sobering 10 million people worldwide per year and causing 1.6 million deaths annually [1]. The large majority of cases are seen in Sub-Saharan Africa and in other low-and-middle-income countries (LMIC) with strained health systems. The search for affordable diagnostic tools is therefore a pressing topic for these countries. Over the past years, increasing migration also brought TB patients to Europe, requiring European hospitals and physicians to diagnose a disease [2], which used to be considered either “historical” or “tropical.”
